NSCLC, ICIs

Phase 1b study of telisotuzumab vedotin in combination with osimertinib for NSCLC

Yakup Ergün Medical Oncologist at Antalya City Hospital shared on X:

“Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met–overexpressing, EGFR-mutated locally advanced/metastatic NSCLC after progression on prior osimertinib

ORR 50%
G3-4 Pulmonary embolism 8%!”

Phase 1b study of telisotuzumab vedotin in combination with osimertinib for NSCLC

Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein–overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib – Annals of Oncology

Authors: H. Horinouchi,  B.C. Cho, D.R. Camidge, K. Goto, P. Tomasini, Y. Li, A. Vasilopoulos, P. Brunsdon, D. Hoffman, W. Shi, E. Bolotin, V. Blot, J. Goldman

Phase 1b study of telisotuzumab vedotin in combination with osimertinib for NSCLC

 

A. Vasilopoulos B.C. Cho cancer D. Hoffman D.R. Camidge E. Bolotin H. Horinouchi J. Goldman K. Goto NSCLC OncoDaily Oncology P. Brunsdon P. Tomasini V. Blot W. Shi Y. Li Yakup Ergün